Showing results (151-160 of 174) with videos related to
Sort By:
Pageof 18
International Journal of Oncology|December 6, 2017
p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trialAmir Sonnenblick, Roberto Salgado, Sylvain Brohée, et al.Cancer|December 8, 2020
Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1-98 clinical trialJose P Leone, Bernard F Cole, Meredith M Regan, et al.European Journal of Cancer (Oxford, England : 1990)|January 26, 2007
Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC)Rosa Giuliani, Virginie Durbecq, Angelo Di Leo, et al.The Lancet. Oncology|December 11, 2017
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trialAngelo Di Leo, Stephen Johnston, Keun Seok Lee, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2015
Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but AlsoJohn M S Bartlett, Christopher C McConkey, Alison F Munro, et al.Journal of the National Cancer Institute|February 23, 2018
Immune Infiltration in Invasive Lobular Breast CancerChristine Desmedt, Roberto Salgado, Marco Fornili, et al.International Journal of Cardiology|August 29, 2020
Catheterization laboratory activity before and during COVID-19 spread: A comparative analysis in Piedmont, Italy, by the Italian Society of Interventional Cardiology (GISE)Giorgio Quadri, Andrea Rognoni, Enrico Cerrato, et al.Breast Cancer Research and Treatment|April 11, 2020
Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapyKarin Ribi, Weixiu Luo, Barbara A Walley, et al.The Pharmacogenomics Journal|February 7, 2019
DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patientsMarzia Del Re, Saverio Cinieri, Angela Michelucci, et al.The Oncologist|April 25, 2015
Defining breast cancer intrinsic subtypes by quantitative receptor expressionMaggie C U Cheang, Miguel Martin, Torsten O Nielsen, et al.Pageof 18